Lipid peroxidation in type 2 diabetes: Relationship with macrovascular disease?

Netherlands Journal of Medicine

Volumn 53, Issue 2, 1998, Pages 61-68

  Oranje, W A ^a   Rondas Colbers, G J W M ^a   Swennen, G N M ^a   Wolffenbuttel, B H R ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Lipid peroxidation; Macrovascular disease; Type 2 diabetes

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN M ANTIBODY; OXIDIZED LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HYPERGLYCEMIA; LIPID PEROXIDATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATION; VASCULAR DISEASE;

AGED; ANALYSIS OF VARIANCE; ARTERIOSCLEROSIS; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LIPID PEROXIDATION; MALE; MIDDLE AGED; NETHERLANDS; PERIPHERAL VASCULAR DISEASES; REFERENCE VALUES; STATISTICS, NONPARAMETRIC; THIOBARBITURIC ACID REACTIVE SUBSTANCES; VITAMIN E;

EID: 0031851284     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-2977(98)00066-7     Document Type: Article

References (44)

1. Palinski W, Rosenfeld ME, Yla-Herttuala S, et al. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA 1989;86:1372-1376.
2. Reaven P. The role of oxidation of LDL in atherogenesis. Endocrinologist 1995;5:44-54.
3. Jansen H, Ghanem H, Kuypers JHSAM, Birkenhäger JC. Autoantibodies against malondialdehyde-modified LDL are elevated in subjects with an LDL subclass pattern B. Atherosclerosis 1995;115:255-262.
4. Maggi E, Chiesa R, Melissano G, et al. LDL oxidation in patients with severe carotid atherosclerosis. Arteriosclerosis 1994;14:1892-1899.
5. Bellomo G, Maggi E, Poli M, Agosta FG, Bollati P, Finardi G. Autoantibodies against oxidatively modified low-density lipoproteins in NIDDM. Diabetes 1995;44:60-66.
6. Salonen JT, Yla-Herttuala S, Yamamoto R, et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992;339:883-887.
7. Dimitriadis E, Griffin M, Owens D, Johnson A, Collins P, Tomkin GH. Oxidation of low-density lipoprotein in NIDDM: its relationship to fatty acid composition. Diabetologia 1995;38:1300-1306.
8. Griesmacher A, Kindhauser M, Andert SE, et al. Enhanced serum levels of thiobarbituric-acid-reactive substances in diabetes mellitus. Am J Med 1995;98:469-475.
9. Altomare E, Vendemiale G, Chicco D, Procacci V, Cirelli D. Increased lipid peroxidation in type 2 poorly controlled diabetic patients. Diabete Metab 1992;18:264-271.
10. Babiy AV, Gebicki JM, Sullivan DR, Willey K. Increased oxidizability of plasma lipoproteins in diabetic patients can be decreased by probucol therapy and is not due to glycation. Biochem Pharmacol 1992;43:995-1000.
11. Cestaro B, Gandini R, Viani P, et al. Fluorescence-determined kinetics of plasma high oxidisability in diabetic patients. Biochem Mol Biol Int 1994;32:983-994.
12. WHO Expert Committee on Diabetes Mellitus: Second report, 1985.
13. Rose GA, Blackburn H, Gillum RF, Prineas RJ. Cardiovascular survey methods. 2nd edn. World Health Organization, 1982.
14. Naito C, Kawamura M, Yamamoto Y. Lipid peroxides as the initiating factor of atherosclerosis. Ann NY Acad Sci 1993;676:27-45.
15. Esterbauer H, Striegl G, Puhl H, Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Rad Res Comm 1989;6:67-75.
16. Oostenbrug G, Mensink R, Hardeman M, De Vries T, Brouns F, Hornstra G. Exercise performance, red blood cell deformability, and lipid peroxidation: effects of fish oil and vitamin E. J Appl Physiol 1997;83:746-752.
17. Rumsey SC, Galeano NF, Arad Y, Deckelbaum RJ. Cryopreservation with sucrose maintains normal physical and biological properties of human plasma low density lipoproteins. J Lipid Res 1992;33:1551-1561.
18. Terpstra AHM, Woodward CJH, Sanchez-Muniz FJ. Improved techniques for the separation of serum lipoproteins by density gradient ultracentrifugation: visualization by prestaining and rapid separation of serum lipoproteins from small volumes of serum. Anal Biochem 1981;111:149-157.
19. Watanabe N. Urinary protein as measured with a pyrogallol red-molybdate complex, manually and in a Hitachi 726 automated analyzer. Clin Chem 1986;32:1544-1551.
20. Kleinveld HA, Hak-Lemmers HLM, Stalenhoef AFH, Demacker PNM. Improved measurement of low-density-lipoprotein susceptibility to copper-induced oxidation: application of a short procedure for isolating low-density lipoprotein. Clin Chem 1992;38:2066-2072.
21. Bieri J, Tolliver T, Contignani G. Simultaneous determination of alfa-tocopherol and retinol in plasma or red cells by high pressure liquid chromatography. Am J Clin Nutr 1979;32:2143-2149.
22. Williamson JR, Chang K, Frangos M, et al. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 1993;42:801-813.
23. Giugliano D, Ceriello A. Oxidative stress and diabetic vascular complications. Diabetes Care 1996;19:257-267.
24. Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA 1993;90:6434-6438.
25. Gallou G, Ruelland A, Campion L, et al. Increase in thiobarbituric acid-reactive substances and vascular complications in type 2 diabetes mellitus. Diabete Metab 1994;20:258-264.
26. Velasquez E, Winocour PH, Kesteven P, Alberti KGMM, Laker MF. Relation of lipid peroxides to macrovascular disease in type 2 diabetes. Diabetic Med 1991;8:752-758.
27. Niskanen LK, Salonen JT, Nyyssonen K, Uusitupa MIJ. Plasma lipid peroxidation and hyperglycaemia: a connection through hyperinsulinaemia?. Diabetic Med 1995;12:802-808.
28. Beaudeux JL, Guillausseau PJ, Peynet J, et al. Enhanced susceptibility of low-density lipoprotein to in vitro oxidation in type 1 and type 2 diabetic patients. Clin Chim Acta 1995;239:131-141.
29. Yoshida H, Ishikawa T, Nakamura H. Vitamin E/Lipid peroxide ratio and susceptibility of LDL to oxidative modification in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vase Biol 1997;17:1438-1446.
30. Mol MJTM, De Rijke YB, Demacker PNM, Stalenhoef AFH. Plasma levels of lipid and cholesterol oxidation products and cytokines in diabetes mellitus and cigarette smoking: effects of vitamin E treatment. Atherosclerosis 1997;129:169-176.
31. Dean JD, Julier K, Mackness MI, Durrington DN. The susceptibility of LDL and HDL from patients with diabetes mellitus to in vitro oxidative modification. Diab Med 1994;11:813.
32. De Graaf J, Hendriks JCM, Demacker PNM, Stalenhoef AFH. Identification of multiple dense LDL subfractions with enhanced susceptibility to in vitro oxidation among hypertriglyceridemic subjects. Arteriosclerosis 1993;13:712-719.
33. Nourooz-Zadeh J, Rahimi A, Tajaddini-Sarmadi J, et al. Relationships between plasma measures of oxidative stress and metabolic control in NIDDM. Diabetologia 1997;40:647-653.
34. Sundaram R, Bhaskar A, Vijayalingam S, Viswanathan M, Mohan R, Shanmugasundaram K. Antioxidant status and lipid peroxidation in type 2 diabetes mellitus with and without complications. Clin Sci 1996;90:255-260.
35. Maxwell S, Thomason H, Sandler D, et al. Antioxidant status in patients with uncomplicated insulin-dependent and non-insulin-dependent diabetes mellitus. Eur J Clin Invest 1997;27:484-490.
36. Traber M, Sies H. Vitamin E in humans: demand and delivery. Ann Rev Nutr 1996;16:321-347.
37. Breugnot C, Maziere C, Auclair M, et al. Calcium antagonists prevent monocyte and endothelial cell-induced modification of low density lipoproteins. Free Rad Res Comm 1991;15:91-100.
38. Zieden B, Wuttge DM, Karlberg BE, Olsson AG. Effects of in vitro addition of captopril on copper-induced low density lipoprotein oxidation. Br J Clin Pharmacol 1995;39:201-203.
39. Croft K. Low density lipoprotein composition and oxidizability in coronary disease - apparent favourable effect of beta blockers. Atherosclerosis 1992;97:123-130.
40. Sanderson KJ, Rij AM, Wade CR, Sutherland WHF. Lipid peroxidation of circulating low density lipoproteins with age, smoking and in peripheral vascular disease. Atherosclerosis 1995;118:45-51.
41. Craig WY. Autoantibodies against oxidized low density lipoprotein: a review of clinical findings and assay methodology. J Clin Lab Anal 1995;9:70-74.
42. Griffin M, McInerney D, Fraser A, et al. Autoantibodies to oxidized low density lipoprotein: the relationship to low density lipoprotein fatty acid composition in diabetes. Diab Med 1997;14:741-747.
43. Uusitupa MIJ, Niskanen L, Luoma J, et al. Autoantibodies against oxidized LDL do not predict atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vase Biol 1996;16:1236-1242.
44. Virella G, Virella I, Leman RB, Pryor MB, Lopes-Virella MF. Anti-oxidized low-density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers. Int J Clin Lab Res 1993;23:95-101.